DrugDashboards

Ciclopirox

ciclopirox · CICLOPIROX 80 mg/mL · Solution · Topical · Encube Ethicals, Inc.

NDC 21922-0053-51 · 1 BOTTLE, WITH APPLICATOR in 1 CARTON / 6.6 mL in 1 BOTTLE, WITH APPLICATOR · ANDA · View full market →

The short version

8 companies supply this market — a reasonable cushion if one runs into trouble. The price is down 22% over the past year, to $1.17 per mL. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$1.17per MLinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$3.34per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$2.85per unitnegotiated price across 4,418 plans — before rebates · Apr 1, 2026
  • Medicaid generic ceiling (FUL)$1.17per MLweighted avg manufacturer price $0.4553 · Aug 1, 2026100% of what pharmacies pay — higher than 10% of drugs with this benchmark

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$2.85per unit
middle half $2.02$4.07 · 4,418 plans · Apr 1, 2026
Est. net of rebates
≈ $2.85
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
80%of plans cover it
tier 2 · prior auth 2% · step therapy 0% · qty limit 59%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 1 quarter since 2024.

NADAC price per unit

$0$1.00$2.00$3.00Jan 2024Sep 2026$1.17
33 price points · per ML · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Medicaid spend (2025)

$2.8M
141,885 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

8Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • price down 21% year over year+8

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for ciclopirox (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA077687
TE code
AT
Approval date
Sep 18, 2007
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of ciclopirox (Solution)

LabelerStrengthFirst seenLast seen
Bryant Ranch PrepackCICLOPIROX 80 mg/mLJul 15, 2026Sep 3, 2026
A-S Medication SolutionsCICLOPIROX 80 mg/mLJul 15, 2026Sep 2, 2026
Acella Pharmaceuticals, LLCCICLOPIROX 80 mg/mLJul 15, 2026Sep 2, 2026
Chartwell RX, LLCCICLOPIROX 71.3 mg/mLJul 15, 2026Sep 2, 2026
Encube Ethicals, Inc.CICLOPIROX 80 mg/mLJul 15, 2026Sep 2, 2026
Padagis Israel Pharmaceuticals LtdCICLOPIROX 80 mg/mLJul 15, 2026Sep 2, 2026
Preferred Pharmaceuticals Inc.CICLOPIROX 80 mg/mLJul 15, 2026Sep 2, 2026
Preferred Pharmaceuticals, Inc.CICLOPIROX 80 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Ciclopirox — NDC 21922-0053-51," retrieved September 3, 2026, https://drugdashboards.com/drug/21922005351.

Free to cite with attribution — see how the data is put together.